Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Frontiers Media SA full text link Frontiers Media SA Free PMC article
Full text links

Actions

Share

.2021 Sep 1:3:732318.
doi: 10.3389/frph.2021.732318. eCollection 2021.

Anabolic Androgenic Steroids Induce Reversible Left Ventricular Hypertrophy and Cardiac Dysfunction. Echocardiography Results of the HAARLEM Study

Affiliations

Anabolic Androgenic Steroids Induce Reversible Left Ventricular Hypertrophy and Cardiac Dysfunction. Echocardiography Results of the HAARLEM Study

Diederik L Smit et al. Front Reprod Health..

Abstract

Background: The use of anabolic androgenic steroids (AAS) is not uncommon among strength athletes. Several cross-sectional studies have linked AAS use to heart disease, but a causal role for AAS is not certain and it is unknown whether cardiac changes are reversible.Methods: Men of at least 18 years old intending to start an AAS cycle on short notice were included for comprehensive 3D echocardiographic examination before (T0), at the end of the cycle (T1), and 1 year after inclusion (T2) after a recovery period. Details of the AAS cycle performed and the use of other performance and image-enhancing drugs (PIEDs) as well as illicit drug use were recorded. Trend analysis and multivariable regression analysis were performed with mixed effects linear models.Results: Thirty-one subjects were included. Between start (T0) and end of the cycle (T1), after a median AAS cycle duration of 16 weeks, 3D left ventricular ejection fraction declined with 4.9% (CI -7.2 to -2.5,P < 0.001), E/A-ratio declined with-0.45 (CI -0.69 to -0.21,P < 0.001), and 3D left atrial volume increased with 9.2 ml (CI 2.9-15.4,P = 0.004). Left ventricular mass increased with 28.3 g (CI 14.2-42.4,P < 0.001) and was positively correlated with AAS average weekly dose. After a median recovery time of 8 months (T2), all parameters returned to baseline.Conclusion: AAS induce left ventricular hypertrophy and impaired systolic and diastolic function in amateur strength athletes. The structural cardiac changes are positively associated with AAS dose and complete recovery occurred after AAS were discontinued.

Keywords: anabolic steroids; bodybuilding; performance and image-enhancing drugs; strength athletes; three-dimensional echocardiography.

Copyright © 2021 Smit, Voogel, Heijer and Ronde.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Box and whisker plots of the relevant parameters measured with echocardiography before (T0) and at the end of the cycle (T1) with AAS, and after the recovery period (T2). *P < 0.01.(A) 3D LVEF (%).(B) E/A-ratio.(C) E/e'-ratio lat.(D) E/e'-ratio sept.(E) LAvol 3D (ml).(F) LAD PSLAX (mm).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. (2014) 24:383–98. 10.1016/j.annepidem.2014.01.009 - DOI - PubMed
    1. Piacentino D, Kotzalidis GD, del Casale A, Rosaria Aromatario M, Pomara C, et al. . Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Curr Neuropharmacol. (2015) 13:101–21. 10.2174/1570159X13666141210222725 - DOI - PMC - PubMed
    1. Woodward C, Smith J, Acreman D, Kumar N. Hepatocellular carcinoma in body builders; an emerging rare but serious complication of androgenic anabolic steroid use. Ann Hepatobiliary Pancreat Surg. (2019) 23:174–7. 10.14701/ahbps.2019.23.2.174 - DOI - PMC - PubMed
    1. Smit DL, de Hon O, Venhuis BJ, den Heijer M, de Ronde W. Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids. Scand J Med Sci Sports. (2019) 30:531–9. 10.1111/sms.13592 - DOI - PubMed
    1. Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, et al. . Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction. (2015) 110:823–31. 10.1111/add.12850 - DOI - PMC - PubMed

Related information

LinkOut - more resources

Full text links
Frontiers Media SA full text link Frontiers Media SA Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp